Assess the Safety and Tolerability of SNS851 in Healthy Participants

Sponsor
Oneness Biotech Co., Ltd.
Study ID
NCT07417124
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metabolic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • SNS851 — DRUG
    SNS851 is a potent siRNA treatment targeting metabolic diseases.
  • Placebo — OTHER
    Normal saline

Study Details

This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.

Key Dates

First listed
Feb 18, 2026
Start date
Apr 1, 2026
Status verified
Jun 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
52 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SNS851
    Eligible participants will be assigned to receive low-high single or multiple doses of the investigational drug.
  • Placebo Comparator: Placebo
    Eligible participants will be assigned to single or multiple doses of the placebo.

Primary Outcome Measure

Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: 3 months after last dose (6 months after last dose only for the last MAD cohort) ]

Central Contacts

Related Studies